相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of compound mutations I1171N+F1174I and I1171N+L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights
Elliasu Y. Salifu et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)
Overcoming resistance by ALK compound mutation (I1171S+G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer
Ken Takahashi et al.
THORACIC CANCER (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations
Jing Tu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Koutaroh Okada et al.
EBIOMEDICINE (2019)
Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase
Cheng-Han Jiang et al.
MOLECULES (2018)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naive ALK rearranged lung cancers
Antonio R. Lucena-Araujo et al.
LUNG CANCER (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK plus tumors
Amit Dipak Amin et al.
ONCOTARGET (2016)
Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
Zilan Song et al.
ACTA PHARMACEUTICA SINICA B (2015)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Emerging importance of ALK in neuroblastoma
Anna M. Azarova et al.
SEMINARS IN CANCER BIOLOGY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
分享论文
